Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors
  • Library

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, China
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Our sub-categories
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2025
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Galderma Insights
    • Podcasts
  • Innovation
    • Bringing innovation to life
    • Partnerships
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Investors
You searched for: «【✈️ Telegram ID: KPU77】 대성피 성인 피시방 안전 보장 100% 알거래 중개소 리스트 - 용인»
Results 141 - 145 of 155
Page 29 of 31
  1. Media
  2. Newsroom

Galderma to become the world’s largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health

  • Galderma well positioned for long-term growth in highly attractive dermatology sector

  • Experienced management team and Board to build on strong Galderma foundations

  • Dr. Flemming Ornskov (ex-Shire and Bayer) appointed CEO and Thomas Dittrich appointed CFO (ex-Shire and Amgen)

  1. Media
  2. Newsroom

Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual meeting

FORT WORTH, Texas, Mar. 25, 2022 /PRNewswire/ -- Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates.

  1. Media
  2. Newsroom

Galderma global research reveals struggles of people with rosacea and psoriasis of the face experiencing a lack of control and impact on mental wellbeing

Healthcare professionals (HCPs) encouraged to investigate true impacts beyond the visible, empower patients with knowledge and aim for ‘clear’ (IGA 0) skin to improve outcomes

  1. Media
  2. Newsroom

IMCAS 2023: Galderma to share latest data demonstrating high aesthetic improvement and patient satisfaction across its innovative portfolio

  • Galderma will share exciting results from the Sculptra® Cheek Wrinkle study showing the long-lasting effectiveness and safety of Sculptra, as well as high aesthetic improvement and patient satisfaction over two years[i]  

 

  • The company will also present 10 research poster

  1. Media
  2. Newsroom

AMWC 2026: Galderma showcases category‑leading innovation with a comprehensive portfolio and holistic, future‑focused aesthetic strategies

  • Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9
  • The data reinforce Galderma’s future-focused approach to innovation, addres
Results 141 - 145 of 155
Page 29 of 31

Pagination

  • Previous page Previous Page
  • Next page Next Page
  1. Home
  2. Search results

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2026

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back